Journal
MEDICAL HYPOTHESES
Volume 116, Issue -, Pages 111-113Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.mehy.2018.05.005
Keywords
-
Categories
Funding
- Shanghai Sailing Program [17YF1425200]
- Chinese National Natural Science Funding [81702249]
- Young Start-up Foundation of Changzheng Hospital [2015CZQN07]
- Shanghai Municipal health and Family Planning Commission Foundation [201540174]
Ask authors/readers for more resources
Immune checkpoint inhibitors have profoundly altered the therapeutic landscape of several malignancies. The establishment of predictive biomarkers for checkpoint blockades is of the considerable importance in the identification of populations likely to experience a good response to immunotherapy and to maximize the therapeutic benefits. Several trials showed that the tumor mutation burden (TMB) could predict the response to immunotherapy, but some lower clinical benefit was also seen in cancer with high TMB. The imbalance between the strength of immune response and pretreatment tumor burden (TB) could also cause immunotherapy to fail in cancer patients. For this reason, we hypothesized that the TMB-TB ratio could predict the clinical benefit of checkpoint inhibitor immunotherapy and that PFS or ORRs should be used more often in patients with high TMB-TB ratio than in individuals with low TMB-TB ratios.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available